Batiraxcept

巴替瑞西普

Report date: 2025/02/26 16:44:49

Base Information

Drug NameBatiraxcept
Drug Alias NameAxl fc fusion protein AVB-S6-500AVB-500Aravive S-6AVB-S6-500Ruga-S6 +[11] 
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionGrowth arrest-specific protein 6 inhibitorsAXL receptor tyrosine kinase inhibitors
TargetsGrowth arrest-specific protein 6AXL receptor tyrosine kinase
Therapy Area/IndicationsSolid tumoursGlomerulonephritis, IGAUterine Neoplasms +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[12] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesAravive Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesAravive Inc3d Medicines IncThe University Of Oklahoma +[4] 
Inactive CompaniesWashington University School Of MedicineThe University Of Texas MD Anderson Cancer Center
Active IndicationsSolid tumoursOvarian NeoplasmsCarcinoma, Transitional Cell
Inactive IndicationsGlomerulonephritis, IGAUterine NeoplasmsFallopian Tube Neoplasms +[8] 

Other Information

ATC CodeN/A
Related LinksN/A